Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.


$40m MKT CAP with no earnings.Take a close look at a micro micro micro cap stock that may double in market cap over the next 12 months.

Dry eye diagnostic device that will help drugs get approved before the FDA.  The device will be used to measure endpoints in FDA trials.

The device will also get used by physicians to measure patients susceptibility to dry eye disease.

2 Important catalysts:

1.  CLIA waiver is expected by year end.  HUGE!
This designation will promote mass adaption in the U.S. market.

2. Reimbursement decision expected at year end.

Both are very important for the stock to rise.  The risk is these decision always take longer than expected.  The comapny hoped to get CLIA last year, so the time maybe right for approval. 

Future is unlimited.  The platform can get into other areas to diagnose allergies and other eyes diseases.